IDMIT, for “Infectious Disease Models and Innovative Therapies” is a national Research and Technological infrastructure for biology and health dedicated to preclinical research on infectious diseases (Executive Director: Dr. Roger Le Grand).
IDMIT results from the joint motivation and expertise of the Life Sciences Division of the CEA, Institut Pasteur, Institut National de la Santé et de la Recherche Médicale (Inserm), Agence Nationale de Recherche sur les maladies infectieuses émergentes (ANRS), Université Paris-Saclay and the private company Oncodesign Service.
IDMIT is a unique center in Europe dedicated to infectious disease modeling and preclinical development. IDMIT develops preclinical research programs on human vaccines and antimicrobial treatments and provides our academic and industrial partners with access to facilities and cutting-edge equipement for R&D projects.
IDMIT is grouping scientists of diverse expertises (physicians in charge of clinical research programs, preclinical experts, biochemists, immunologists, microbiologists, physicists and bio-physicists, veterinarians, informatics and bio-informatics experts), to favor integrated research programs from basic biology to preclinical and clinical studies in the fields of human immunology, autoimmunity, antibiotic resistance and human infections.
The unit is implemented in two sites with highly specialized labs and facilities, for preclinical research at FAR (particularly facilities for preclinical studies using non-human primate), and for clinical research at Bicêtre school of medicine.
The major objective of IDMIT consortium is to provide the national and international scientific community with a highly competitive infrastructure for preclinical research, facilitating the discovery of markers of safety and efficacy for new vaccines, treatments and countermeasures and accelerating the translation of innovations from the bench into clinical practice.